Free tool
FAERS Monitor: Absorica Ld
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 211913 or its brand name (Absorica Ld, Isotretinoin). Reports on generic versions are filed under their own applications.
Reports
16,326
Serious
8,845
54% of reports
Hospitalization
1,411
Death reported
439
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- depression1,058
- pregnancy1,040
- exposure during pregnancy775
- abortion induced728
- adverse drug reaction670
- product dose omission issue626
- headache578
- dry skin577
- arthralgia563
- suicidal ideation535
- drug ineffective521
- mood altered467
- anxiety415
- off label use353
- maternal exposure during pregnancy327
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 124 |
| 2005 | 209 |
| 2006 | 355 |
| 2007 | 491 |
| 2008 | 766 |
| 2009 | 503 |
| 2010 | 492 |
| 2011 | 276 |
| 2012 | 383 |
| 2013 | 260 |
| 2014 | 158 |
| 2015 | 197 |
| 2016 | 229 |
| 2017 | 245 |
| 2018 | 389 |
| 2019 | 394 |
| 2020 | 691 |
| 2021 | 1,033 |
| 2022 | 1,547 |
| 2023 | 1,709 |
| 2024 | 2,199 |
| 2025 | 2,321 |
| 2026 | 1,355 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,037,833 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| abortion inducedSignal | 728 | 107.9 | 100.2 | 71,057 |
| pregnancySignal | 1,040 | 70.5 | 66.4 | 67,586 |
| mood alteredSignal | 467 | 22.4 | 20.5 | 9,387 |
| exposure during pregnancySignal | 775 | 16.3 | 15.2 | 10,974 |
| adverse drug reactionSignal | 670 | 9.7 | 9.0 | 5,186 |
| suicidal ideationSignal | 535 | 7.6 | 7.0 | 3,038 |
| depressionSignal | 1,058 | 6.0 | 5.7 | 4,445 |
| dry skinSignal | 577 | 5.6 | 5.2 | 2,174 |
| maternal exposure during pregnancySignal | 327 | 4.7 | 4.3 | 962 |
| product dose omission issueSignal | 626 | 2.7 | 2.5 | 702 |
| anxiety | 415 | 1.9 | 1.7 | 172 |
| arthralgia | 563 | 1.7 | 1.6 | 182 |
| headache | 578 | 1.2 | 1.1 | 17 |
| off label use | 353 | 0.5 | 0.5 | 163 |
| drug ineffective | 521 | 0.5 | 0.5 | 262 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.